From all of us at Med-IQ, we wish you a season filled with peace, joy, and good health. We thank you for your commitment to advancing healthcare excellence and patient safety, and look forward to supporting your goals in 2026! Have a safe and wonderful holiday, and a happy new year!

@med-iq.bsky.social #RiskTipTuesday: #Debriefing breaks down silos, strengthens teams, and leads to safer care. Learn about practical strategies for building a culture of safety in our full blog: link.med-iq.com/2wmEKs #PatientSafety #TeamPerformance #HealthcareLeadership

Thank you to Dr. Ahmad Masri for his live updates on emerging and potentially practice-changing clinical data on advances in the treatment of #ATTR-CM from #AHA25. Check out this thread for highlights. #CardioBluesky #MedIQAHA25

1/22 In this #CME, Dr. Milind Desai provides guidance on #oHCM, including making the diagnosis, staying up-to-date on cardiac myosin inhibitors, and addressing patients’ concerns. Get credit: link.med-iq.com/oXPP2o

1/22 In this #CME #MedX, Matthew W. Martinez, MD, FACC, provides guidance for managing HCM, from symptoms to diagnosis and treatment, and explores when oHCM may be hiding in plain sight. Participate for credit: link.med-iq.com/7mpkl9 Supported by an educational grant from Bristol Myers Squibb.

Thank you to Ahmad Masri, MD, for his live updates on emerging and potentially practice-changing clinical data on advances in the treatment of #ATTR-CM from #HFSA2025. Check out this thread for highlights. #MedIQHFSA2025

Thank you to Ahmad Masri, MD, for his live updates on ATTR-CM from #ESC2025. Check out this thread for highlights! #Transthyretinamyloidcardiomyopathy #Cardiomyopathy #Amyloidosis #MedIQESCCongress #ESCCongress #CardioSky #MedSky

Location, location, location! New in European Heart Journal: Sex-dependent body fat deposition patterns influence the pace of #CV ageing, w/estrogen providing protective effects. Read here: doi.org/10.1093/eurh... #EHJ #CardioSky #MedSky

Sharing an important initiative from @accintouch.bsky.social #HeartHealth #Cardiology

New AHA/ACC #hypertension guidelines! Key updates: • Use of PREVENT calculator (no race-based recs) • Screen for hyperaldosteronism in all pts w/resistant HTN • Push for single-pill combos, home BP monitoring, multidisciplinary mgmt & community care

Ultraprocessed foods are connected with cardiometabolic disease, chronic illness, mortality risk. What are they exactly & are they all bad? New AHA guidance provides some insight, nuance. Helpful framing or mixed messaging? Read more here: www.ahajournals.org/doi/full/10.... #CardioSky

ICYMI: 10,000 steps/day goal gets a rethink in @thelancetph.bsky.social. Clinically meaningful reduction in CVD incidence & death associated w/ just 7,000 steps/day is a much more realistic target for some patients! www.thelancet.com/journals/lan... #Cardiosky #Medsky

2° analysis of 1yr tirzepatide tx for obesity & #HFpEF in SUMMIT trial: • Pts w/⬆️baseline BMI: greater ⬆️6MWD vs placebo • Pts w/⬆️weight loss w/tx: greater ⬆️exercise capacity, sx burden Incretin tx is an important part of HFpEF mgmt! www.jacc.org/doi/10.1016/... #CardioSky #MedSky

Early SHD detection saves lives, ⬇️costs, and ⬆️QoL, but underdx is common. Enter #AI to screen at scale! New in @nature.com: EchoNext, a deep ML ECG-based model: - Accurately ID’d SHD - Outperformed experts - Performed across care settings, pt groups link.med-iq.com/WNCVId #CardioSky #MedSky

Hypertrophic cardiomyopathy (HCM) can be deceptively silent. Join this CME activity, designed to help more clinicians identify HCM early, confidently, and collaboratively through real-world patient journeys from symptom onset to diagnosis. Earn credit link.med-iq.com/OmAZSa @accintouch.bsky.social

From Ahmad Masri, MD et al in JACC Heart Failure: 1-yr FOREST-HCM OLE update Ongoing efficacy of aficamten for #oHCM • No HF events • No new AF • Low rate asx ⬇️LVEF (managed w/ dose reduction) More at #ESC2025! @jaccjournals.bsky.social #CardioSky #MedSky 🔗 Full update: link.med-iq.com/MEKZHn

#Menopause transition (MT) raises sx & cardiometabolic Ds, increasing women's CVD risk but also offers a chance for early prevention. Check @jaccjournals.bsky.social for multidisciplinary guidance to lower MT CV risk! www.jacc.org/doi/10.1016/... #CardioSky #MedSky

Sports physical time! Timely article on professional liability risks w/SCA screening, return2play decisions, and counseling ↑risk athletes on participation choices & adequate rescue plans for potential CV events. www.sciencedirect.com/science/arti... #CardioSky #MedSky

1/43 Welcome to this #CME #Skeetorial on transthyretin amyloid cardiomyopathy (ATTR-CM), including updates in treatment from ACC25, with cardiologist @mkittlesonmd.bsky.social. Earn credit: link.med-iq.com/6h6qnR #Cardiology #CardioEd #MedEd

New in @jama.com _current from @rohankhera.bsky.social et al: AI-enabled echo interpretation w/PanECHO. TL;DR: the validated tool accurately detects a range of CV conditions, even with low-quality POC imaging. Potential gamechanger! #CardioSky #MedSky

ICYMI: an innovative approach to shrink blood clots uses shear forces to spin out RBCs!

More guidance on CV risks of alcohol consumption, this time from @americanheart.bsky.social. An important point: be sure patients understand what “moderate” intake means, and what constitutes 1 drink! #CardioSky

New #cvACS guidelines take center stage in the June 10, 2025 issue of @jaccjournals.bsky.social www.jacc.org/toc/jacc/cur.... More than just #ClinicalGuidelines, check out related expert perspectives, take-home messages, and more! #CardioSky #MedSky

#HCM is often misdiagnosed. This complimentary, CME-accredited activity: spot subtle red flags in HCM, elevate your diagnostic confidence, & know when to escalate for early intervention. clinical.med-iq.com/activity/1936 #Cardiology #Echo #MedEd #CME #CardioSky #MedSky #HypertrophicCardiomyopathy

1/11 Muthu Vaduganathan helped us share insights from #HeartFailure2025. Here are some highlights: #LBCT by Marianna Fontana #HELIOSB Recently FDA approved Vutrisiran RNAi therapeutic reduces mortality through 42 months in #ATTRCM #CardioSky #MedSky #Cardiology

LBCT insights from SEQUOIA-HCM at #HeartFailure2025: #aficamten as effective in mildly symptomatic pts w/ #oHCM (NYHA class II/KCCQ-CSS ≥80) as in pts w/ moderate to severe sx. Now published in EHJ! doi.org/10.1093/eurheartj/ehaf364 #CardioSky #MedSky

New #podcast episode from Med-IQ and Coverys: What happens when AI hallucinates in healthcare settings? -Misinformation -Clinical risk -Care disparities Learn how to spot AI-driven dangers—and counter them. Listen: apple.co/456BLIy #AIinHealthcare #PatientSafety #HealthcarePodcast

ICYMI: Data from Ph3 TANDEM & BROADWAY trials presented last week at #EASCongress25 indicate obicetrapib may be another tool to ↓LDL and Lp(a) in pts w/ASCVD or HeFH. Outcomes data from PREVAIL anticipated early 2026! #CardioSky #MedSky

STEAM meets cardiac rhythm! A new @jaccjournals.bsky.social Clinical Electrophysiology talk uses classical musical notation to describe #arrhythmias as “music of the heart.” A great tool to “hear” different arrhythmias! www.youtube.com/watch?v=FkkE... #CardioSky #MedSky

New study in @jama.com with strong support for discussing genetic testing with patients presenting with early onset AF. Consider using OARS as a communication tool to structure conversations with patients to explore this testing option. jamanetwork.com/journals/jam... #CardioSky #Cardiology

Fine tuning risk prediction scores from deep-learning algorithms on ECGs facilitates AI use in clinical practice to identify patients HCM risk. Individualized info helps better prioritize patients for HCM evaluation. #CardioSky #MedSky #HCM #Cardiology

New data from the MGB Lp(a) Registry re: sex differences in the connection b/w Lp(a) and CV outcomes in pts w/o ASCVD: younger women less likely to experience AEs vs younger men, but risk similar in men and women > 60 years: www.ahajournals.org/doi/10.1161/... #CardioSky #MedSky

ICYMI: engineers developed the world’s smallest light-activated pacemaker. No surgery to implant or retrieve means fewer complications and improved safety, particularly for the smallest cardiac patients! #CardioSky #MedSky

A multidisciplinary team is required to manage #HCM patients. Communication is key. #SharedDecisionMaking plays a vital role from treatment to exercise, nutrition, and management of those who especially want to participate in sports. #CardioSky #Cardiology #MedicalEducation #MedEd

New insights from ongoing AG10-202 OLE study w acoramidis in ATTR-CM: long-term tx assoc w/sustained TTR stabilization and 2/3 of pts had ↓NT-proBNP from baseline after 45 mos. More data to come from Ph3 OLE study cohort! onlinejcf.com/article/S107... #CardioSky

New ACC/AHA ACS mgmt guidelines: 1-stop-shop for ED→discharge *Newer antiplatelets to prevent recurrent MI, death *Aggressive LDL-C lowering *Intracoronary imaging-guided stent placement *Cardiogenic shock tx options www.ahajournals.org/doi/10.1161/... #Cardiosky #Medsky

#ECHO is the mainstay for managing symptomatic patients with #HCM. Ejection fractions, valsalva, and rest are all achieved using ECHO. Patients are enrolled in the REMS, a risk mitigation system to monitor patients over time. #CardioSky #MedEd #Cardiology

If you missed live updates from Ahmad Masri, MD, at #ACC25 on ATTR-CM, view this thread for highlights! #MEDIQACC25 #CardioSky

Not everyone can exercise without guidance, but risk stratification to assess elite or professional athletes can be done to put together an exercise plan for them. #CardioSky #Cardiology #MedicalEducation #MedEd

From #ACC.25 presenter, Milton Packer, MD, and according to results of the SUMMIT trial, #tirzepatide lowers the risk of major HF adverse events & improves health, QoL, & functional capacity, regardless of the presence of CKD. But benefits are greater in those w/ CKD. #CardioSky #ACC25 #Cardiology

STRIDE results from #ACC.25 helps inform tx selection for patients with T2D&PAD: #semaglutide significantly improves walking distance, QoL, reduced PAD progression, improved ABI! Published in Lancet: www.thelancet.com/journals/lan... #CardioSky #MedSky #ACC25

Dr. Masri from #ACC.25. Responders analysis - acoramidis vs placebo for improving NYHA class from the ATTRibute-CM. #ACC25 #CardioSky #Cardiology

Poster from Jan M. Griffin, MD at #ACC.25, “The efficacy of #acoramidis compared w/ placebo was preserved, despite using more stringent thresholds for change in #NT-proBNP to indicate disease progression.” @bridgebiopharma.bsky.social #CardioSky #Cardiology #ACC25

Dr. Masri reporting from #ACC.25 session on the multimodality imaging in cardiac #amyloidosis. Dr. Dia Smiley presenting a case of T60A where #HDP bone scintigraphy was negative, while biopsy was positive. Keep it in my - false negatives exist. #ACC25 #CardioSky #Cardiology @accintouch.bsky.social

#ACC.25 Day 2 highlights continue from Dr. Masri. Delays in transthyretin diagnosis. #CardioSky #ACC25 #Cardiology

More from @BrettSperryMD: Small study, but ECV relationship to amyloid burden with an interaction with T2 relaxation time #ACC.25 #CardioSky

From #ACC.25 and Dr. Masri: A possible working frame why PYP/HDP/DPD uptake decrease over time while cardiac structure/ECV don't change presented by @BrettSperryMD, @sarahcud, @DorbalaSharmila #ACC25 #CardioSky #Cardiology

Dr. Masri also shared from Brett Sperry (@Brett Sperry on X). How to measure amyloid burden. It can get complicated. #ACC.25 #CardioSky

With the delays in diagnosis, maybe the solution is systematic screening in populations at risk. #ACC.25 #CardioSky

Dr. Masri shares from #ACC.25. How does Firas Al Badarin (@falbadarin on X) diagnose transthyretin #cardiac #amyloidosis Recognition is most important: - rule out AL - bone scintigraphy - TTR gene sequencing - selective tissue sampling #ACC25 #CardioSky #Cardiology @accintouch.bsky.social